| Click on green circle(s) for more information. |
| Organization Name | ATSDR |
Health Canada |
IARC |
IPCS |
IPRV |
ITER PR |
NSF Intl |
RIVM |
TCEQ |
U.S.EPA |
|---|---|---|---|---|---|---|---|---|---|---|
| Risk Value Name |
|
|
|
|
|
|
|
|
|
RSD |
| Risk Value (mg/kg-day) |
|
|
|
|
|
|
|
|
|
1.4E-5 |
| Year |
|
|
|
|
|
|
|
|
|
2001 |
| Classification |
|
|
|
|
|
|
|
|
|
B2 |
| Target Organ |
|
|
|
|
|
|
|
|
|
kidney, testis, thyroid tumors |
| Species |
|
|
|
|
|
|
|
|
|
rat |
| Study |
|
|
|
|
|
|
|
|
|
DeAngelo et al., 1998 |
| More Information |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
U.S. EPA has evaluated the carcinogenicity of bromate. EPA classifies this chemical as B2 - probable human carcinogen under its current guidelines (U.S. EPA 1986). The cancer weight of evidence classification is based on all routes of exposure. Under its "Proposed Guidelines for Carcinogen Risk Assessment" (U.S. EPA, 1996), EPA determined that bromate should be evaluated as a likely human carcinogen by the oral route of exposure. EPA estimated an oral slope factor of 7E-1 per (mg/kd-day). TERA has converted the EPA oral slope factor to a risk specific dose (RSD) at the 1 in 100,000 level. The EPA value is converted by dividing 1E-5 by the slope factor of 7E-1 per (mg/kg)/day to determine a RSD of 1.4E-5 mg/kg-day. Click on the green circle(s) for more information.
| Glossary of ITER definitions |
|
ITER Instructions |